Full View

High surface IgM levels associate with shorter response to ibrutinib and BTK bypass in patients with CLL

G Chiodin, S Drennan, EA Martino… - Blood …, 2022 - ashpublications.org
Chronic lymphocytic leukemia (CLL) cells have variably low surface IgM (sIgM)
levels/signaling capacity, influenced by chronic antigen engagement at tissue sites. Within …
被引用次数：5 相关文章

High surface IgM levels associate with shorter response to ibrutinib and BTK bypass in patients with CLL

G Chiodin, S Drennan, EA Martino, L Ondrisova… - BLOOD …, 2022 - iris.unisr.it
Chronic lymphocytic leukemia (CLL) cells have variably low surface IgM (sIgM)
levels/signaling capacity, influenced by chronic antigen engagement at tissue sites. Within …

High surface IgM levels associate with shorter response to ibrutinib and BTK bypass in CLL patients.

G Chiodin, S Drennan, EA Martino, L Ondrisova… - Blood …, 2022 - europepmc.org
Chronic lymphocytic leukemia (CLL) cells have variably low surface IgM (sIgM)
levels/signaling capacity, influenced by chronic antigen engagement at tissue sites. Within …
[HTML] sciencedirect.com

[HTML][HTML] High surface IgM levels associate with shorter response to ibrutinib and BTK bypass in patients with CLL

G Chiodin, S Drennan, EA Martino, L Ondrisova… - Blood Advances, 2022 - Elsevier
Chronic lymphocytic leukemia (CLL) cells have variably low surface IgM (sIgM)
levels/signaling capacity, influenced by chronic antigen engagement at tissue sites. Within …

High surface IgM levels associate with shorter response to ibrutinib and BTK bypass in patients with CLL

G Chiodin, F Forconi, I Henderson… - Blood …, 2022 - eprints.soton.ac.uk
Chronic lymphocytic leukemia (CLL) cells have variably low surface IgM (sIgM)
levels/signaling capacity, influenced by chronic antigen engagement at tissue sites. Within …
[HTML] nih.gov

[HTML][HTML] High surface IgM levels associate with shorter response to ibrutinib and BTK bypass in patients with CLL

G Chiodin, S Drennan, EA Martino, L Ondrisova… - Blood …, 2022 - ncbi.nlm.nih.gov
Chronic lymphocytic leukemia (CLL) cells have variably low surface IgM (sIgM)
levels/signaling capacity, influenced by chronic antigen engagement at tissue sites. Within …

High surface IgM levels associate with shorter response to ibrutinib and BTK bypass in patients with CLL

G Chiodin, S Drennan, EA Martino… - Blood …, 2022 - pubmed.ncbi.nlm.nih.gov
Chronic lymphocytic leukemia (CLL) cells have variably low surface IgM (sIgM)
levels/signaling capacity, influenced by chronic antigen engagement at tissue sites. Within …